NCT00903552View on ClinicalTrials.gov

Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)

PHASE2CompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Seasonal Influenza
Interventions
BIOLOGICAL

Influenza VLP Vaccine

BIOLOGICAL

Placebo

phosphate-buffered saline (PBS)

Trial Locations (2)

21201

SNBL Clinical Pharmacology Center, Baltimore

33024

University Clinical Research, Inc., Pembroke Pines

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY